Grazoprevir plus elbasvir and other treatment options in hepatitis C infected patients with stage 4-5 chronic kidney disease
- PMID: 27867981
- PMCID: PMC5104624
- DOI: 10.21037/atm.2016.10.41
Grazoprevir plus elbasvir and other treatment options in hepatitis C infected patients with stage 4-5 chronic kidney disease
Conflict of interest statement
Dr. KR Bhamidimarri has served on scientific advisory board for Gilead, AbbVie and Bristol-Myers Squibb.
Comment on
-
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.Lancet. 2015 Oct 17;386(10003):1537-45. doi: 10.1016/S0140-6736(15)00349-9. Epub 2015 Oct 5. Lancet. 2015. PMID: 26456905 Clinical Trial.
References
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources